{"ticker": {"uuid": "19261884-00bf-4398-a64d-0a7ee4db03f6", "symbol": "SCNX", "name": "Scienture Holdings, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Pharmaceutical Retailers"}, "articles": [{"title": "Scienture Holdings Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAJBVV95cUxPY0RKYTNtc1dvQVpBVWVzZHlOUDJfTmF3Wi1GQTQ1dExFUjFzU3U2bXlvM0JleUhxaEdEVXBrX3JmYjYxVmlacGRmcVFobFJodEhmT1hLWjVpY0ZtOVg3YWtLMFBOUk4xeTFWOVpIY1B4TC1XeG5OTS1YMWhFRThUaFlMelRPMmtNNGdhWV9JaHdWdkFxcUZ6OFh2dkszbHlQcTVlcndDeXNDUVVXOEROd1ZEdk5Id0xWX3p5LUNDSFVxUURSYzdvNkRIeFFuZUxhbS1WSmNwOGlZV2Q4Rk1ZTnViSE9mZDkyUktLTW00bVRxTGttZ0UyS2gyMDVnZVV3WWp6MGU5YjRDNkM4UVlreXA0MG5EaE1kYmVGRGJJbWhHOEEtUmNZSlluSTlKVFlWYTRmR0V5c29nbDhHRlZKQlBpSm9FUUhD?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T16:14:45+00:00", "published_display": "13 Jul 2026 16:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings (SCNX) Registration filing Summary", "summary": "Scienture Holdings (SCNX) filed a registration summary outlining its strategic shift from a digital pharmacy marketplace to a specialty pharmaceutical company, focusing on CNS and cardiovascular diseases. The company reported a net loss of $4.4 million for the six months ending J", "url": "https://quartr.com/events/scienture-holdings-inc-scnx-registration-filing_F1ZpJ9do", "source_name": "Quartr", "published_at": "2026-07-11T23:12:50", "published_display": "11 Jul 2026 23:12", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on Top Healthcare Stocks: Scienture Holdings (SCNX), Royalty Pharma (RPRX)", "summary": "Two analysts have issued bullish sentiments on healthcare stocks Scienture Holdings (SCNX) and Royalty Pharma (RPRX). Maxim Group analyst Naz Rahman reiterated a Buy rating on Scienture Holdings with a $1.50 price target, while Bank of America Securities analyst Jason Gerberry ma", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3239239/analysts-are-bullish-on-top-healthcare-stocks-scienture-holdings-scnx-royalty-pharma-rprx/", "source_name": "The Globe and Mail", "published_at": "2026-07-11T22:47:05", "published_display": "11 Jul 2026 22:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maxim Group Maintains Scienture Holdings(SCNX.US) With Buy Rating, Maintains Target Price $1.5", "summary": "Maxim Group has reiterated its Buy rating for Scienture Holdings (SCNX.US), maintaining a target price of $1.5. This indicates continued confidence from the analyst firm in the company's stock performance.", "url": "https://www.moomoo.com/news/post/72791205/maxim-group-maintains-scienture-holdings-scnxus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-11T15:40:29", "published_display": "11 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why", "summary": "Scienture Holdings (NASDAQ: SCNX) shares surged over 20% pre-market due to the impending commercial launch of its high-dose naloxone nasal spray, REZENOPY, with shipments to wholesalers expected this month and retail availability in August. This follows a previous successful prod", "url": "https://www.sahmcapital.com/news/content/scienture-holdings-stock-jumps-over-20-pre-market-heres-why-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T13:40:29", "published_display": "11 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings, Inc. Completes Manufacturing of Commercial Launch Inventory and Begins Shipments of Rezenopy Nasal Spray 10 Mg to U.S. Pharmaceutical Wholesalers", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNcWlTQmJYcF9DeDJsRTdOdGtFaGNmNU9ITFFaSDZjMlIySE1QMEpFcEFIMWF4Tl8tcFdMYnN0V3R4b1lfdGNucUVSa2ZpMnl3STVwSXZZbG9GUlpJYk9qMDFmVk9hZW9rX2dFQVRvNkhxQjFSRS1LM0FjdlBEeDZHckpLcnhVM0hZb2ZKRFd3cWUxbEtNZXU4LVRWYjl0OGhfSnZVM2NQUWg5UHBuajBnMUZrVXRSZWxQUzhLY19SbmswNVdYaEdMeDN2RUNJMTBNYjQ5UjhWUFl1eU5wSUhSYnZBck1xUQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-09T16:35:57+00:00", "published_display": "09 Jul 2026 16:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture (SCNX) Prepares for Rezonopy Nasal Spray Launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQcF8yZFlMUEtJczdRRzhoREEyOFBFN05CZzZ0Z1BJaHFfd1B0TkZGZUZPUjB6Z2dQR0pqdFNIRzZ1bkhHSmxNaWRsNUctOUkyekE2amkzZVc0VXNWVUhmdGZrN3FpSEt0UEx4WkVoZ2dJeXdVUkVTNkx2WlByVE4ycFFNd3NENzdTTG5rNVE0TjN0OGxLbTNDS0d3?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-09T14:18:04+00:00", "published_display": "09 Jul 2026 14:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture completes manufacturing for naloxone spray launch", "summary": "Scienture Holdings Inc. has completed manufacturing of REZENOPY naloxone hydrochloride nasal spray 10 mg and will begin shipments to U.S. pharmaceutical wholesalers this month, with commercial availability expected in August. The FDA-approved product targets a U.S. naloxone marke", "url": "https://www.investing.com/news/company-news/scienture-completes-manufacturing-for-naloxone-spray-launch-93CH-4784007", "source_name": "Investing.com", "published_at": "2026-07-09T12:40:53", "published_display": "09 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY\u2122 (naloxone hydrochloride) to Wholesalers", "summary": "SCIENTURE Holdings, Inc. has finished manufacturing commercial inventory for REZENOPY\u2122 (naloxone hydrochloride) Nasal Spray 10 mg and will begin shipments to U.S. pharmaceutical wholesalers later in July. This marks a significant commercial milestone for the company, with REZENOP", "url": "https://www.marketscreener.com/news/scienture-announces-commercial-inventory-readiness-and-july-shipments-of-rezenopya-naloxone-hydro-ce7f5eded98ff323", "source_name": "www.marketscreener.com", "published_at": "2026-07-09T11:40:53", "published_display": "09 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY (Naloxone Hydrochloride) to Wholesalers", "summary": "SCIENTURE Holdings, Inc. announced that it has completed manufacturing of its commercial launch inventory for REZENOPY (naloxone hydrochloride) Nasal Spray 10 mg and will begin shipments to U.S. pharmaceutical wholesalers later in July 2026. Commercial availability for purchase i", "url": "https://www.moomoo.com/news/post/72715872/scienture-announces-commercial-inventory-readiness-and-july-shipments-of-rezenopy", "source_name": "Moomoo", "published_at": "2026-07-09T11:40:53", "published_display": "09 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture readies highest-dose naloxone spray for August sale", "summary": "Scienture (NASDAQ: SCNX) has completed the commercial launch inventory for REZENOPY\u2122 (naloxone hydrochloride) Nasal Spray 10 mg and will begin shipments to U.S. wholesalers in July 2026, with commercial availability expected in August. REZENOPY is the highest-dose FDA-approved na", "url": "https://www.stocktitan.net/news/SCNX/scienture-announces-commercial-inventory-readiness-and-july-gjrls795bwet.html", "source_name": "Stock Titan", "published_at": "2026-07-09T11:40:52", "published_display": "09 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Scienture Holdings, Inc. \u2013 NASDAQ:SCNX", "summary": "The article displays the \"Price to sales forward\" metric for Scienture Holdings, Inc. (NASDAQ: SCNX) on the TradingView platform. It provides a financial metric for the company, accessible through various market data and analysis tools. The page itself is a snapshot of financial ", "url": "https://www.tradingview.com/symbols/NASDAQ-SCNX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T17:42:17", "published_display": "30 Jun 2026 17:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Scienture Holdings, Inc. \u2013 NASDAQ:SCNX", "summary": "This article mentions the \"Price to book forward\" for Scienture Holdings, Inc. (NASDAQ: SCNX). It appears to be a stub or a title for a financial data point without further textual analysis or details provided. The content primarily consists of navigation and copyright informatio", "url": "https://www.tradingview.com/symbols/NASDAQ-SCNX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:27:45", "published_display": "30 Jun 2026 04:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings, Inc. Actuals & Estimates (NASDAQ:SCNX)", "summary": "This article provides an overview of Scienture Holdings, Inc. (SCNX) financial actuals and estimates, including its current stock price, volatility, market cap, and future earnings reports. It details past stock performance, analyst forecasts, and answers frequently asked questio", "url": "https://www.tradingview.com/symbols/NASDAQ-SCNX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:11:13", "published_display": "25 Jun 2026 18:11", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCNX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Scienture Holdings, Inc. (SCNX) stock. An analyst has set a 1-year price target of $1.50, though the stock has seen significant declines over the past year. The article also includes financial data, earnings information, and a", "url": "https://www.tradingview.com/symbols/NASDAQ-SCNX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:10:30", "published_display": "25 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings Inc (SCNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Scienture Holdings Inc (SCNX), highlighting its current price momentum, support and resistance levels, and indicator and moving average signals. It notes that SCNX's stock price is trading between resistance at $0.43 and support at $0", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scnx/technical", "source_name": "TradingKey", "published_at": "2026-06-24T15:09:41", "published_display": "24 Jun 2026 15:09", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCIENTURE Expands Arbli\u2122 Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide", "summary": "SCIENTURE Holdings, Inc. announced a significant expansion in the commercialization of its product, Arbli\u2122 (losartan potassium oral suspension), by securing additional payor coverage for approximately 12.5 million more lives.", "url": "https://finance.yahoo.com/healthcare/articles/scienture-expands-arbli-payor-coverage-120500712.html", "source_name": "Market source", "published_at": "2026-06-22T17:11:25", "published_display": "22 Jun 2026 17:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings (Nasdaq:SCNX) - Stock Analysis", "summary": "This article provides a stock analysis of Scienture Holdings (Nasdaq: SCNX), highlighting its undervaluation, forecast earnings growth, and risks such as shareholder dilution and volatile share price. It details recent commercialization efforts for its drug Arbli and FDA-approved", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-scnx/scienture-holdings", "source_name": "Simply Wall Street", "published_at": "2026-06-21T02:09:10", "published_display": "21 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings Inc (SCNX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Scienture Holdings Inc (SCNX), highlighting its current valuation score of 8.95 within the Pharmaceuticals industry. It details the company's P/E ratio, noting it is significantly below its recent high. The article also mentions that ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scnx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T01:39:25", "published_display": "19 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture stock rises after adding 12.5M covered lives for Arbli", "summary": "Scienture Holdings Inc (NASDAQ: SCNX) shares rose 5.8% after announcing additional payor coverage for its drug Arbli, a losartan potassium oral suspension. This expanded coverage adds approximately 12.5 million covered lives through Medicare Part D and other healthcare channels, ", "url": "https://ng.investing.com/news/stock-market-news/scienture-stock-rises-after-adding-125m-covered-lives-for-arbli-93CH-2565621", "source_name": "Investing.com Nigeria", "published_at": "2026-06-19T00:39:50", "published_display": "19 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings Inc (SCNX) Institutional Confidence", "summary": "This article from TradingKey provides an overview of the institutional confidence in Scienture Holdings Inc (SCNX), specifically detailing changes in institutional shareholdings. Several individuals and firms, including Narasimhan (Mani), Hariharan (Shankar Ph.D.), and Geode Capi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scnx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T13:10:24", "published_display": "18 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings Inc (SCNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article provides a revenue breakdown for Scienture Holdings Inc (SCNX), noting that relevant data for business segments and regional revenue contribution has not yet been disclosed by the company for FY2025 and earlier quarters. It highlights that the company's stock closed a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scnx/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T12:39:02", "published_display": "18 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX)", "summary": "Analysts are split on their ratings for healthcare companies Moderna (MRNA) and Scienture Holdings (SCNX). William Blair analyst Myles Minter reiterated a Hold rating for Moderna, while Maxim Group analyst Naz Rahman reiterated a Buy rating for Scienture Holdings with a $1.50 pri", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MRNA-Q/pressreleases/2519934/analysts-conflicted-on-these-healthcare-names-moderna-mrna-and-scienture-holdings-scnx/", "source_name": "The Globe and Mail", "published_at": "2026-06-18T12:39:01", "published_display": "18 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture expands payor coverage for Arbli by 12.5M lives", "summary": "Scienture Holdings Inc. has announced a significant expansion in payor coverage for its oral suspension, Arbli, adding approximately 12.5 million covered lives through Medicare Part D supplement plans and other commercial and government healthcare channels. This move aims to incr", "url": "https://www.investing.com/news/company-news/scienture-expands-payor-coverage-for-arbli-by-125m-lives-93CH-4749779", "source_name": "Investing.com", "published_at": "2026-06-18T12:10:49", "published_display": "18 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture (SCNX) Advances Commercialization of Arbli", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNbUNCNUVWbS1WRFNKZEpla0hfWWFPeFF0amQ0bmdrYV9pck9NQnpadlhDeGEzM3RXenBHNnZ1ZUZ0RTloMUpYdHhZZnYxZXFCX1lVNEd2R2tWenlTS0p2bWJkYTlOQW5pNnRxcHFCR1hUYUwxVWszX3hXb3FXNnNGZFAyU0ZyQTRyWUJ3TlFUX1dFbmp2QTFKcmw2RWx6elhDVHY4?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings Inc (SCNX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Scienture Holdings Inc (SCNX) currently holds a financial score of 6.07, ranking 148th out of 157 in the Pharmaceuticals industry, indicating robust financial status but low operating efficiency. The company recently reported a quarterly revenue of 56.33K, marking a significant y", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scnx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T06:10:09", "published_display": "18 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCIENTURE Expands Arbli Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide", "summary": "SCIENTURE has significantly expanded payor coverage and commercial access for its medication, Arbli, adding approximately 12.5 million covered lives across the nation. This expansion includes new agreements with major payors like Capital Blue Cross in Pennsylvania and Excellus Bl", "url": "https://www.moomoo.com/news/post/71732053/scienture-expands-arbli-payor-coverage-and-commercial-access-adding-approximately", "source_name": "Moomoo", "published_at": "2026-06-18T06:09:20", "published_display": "18 Jun 2026 06:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings Inc (SCNX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Scienture Holdings Inc (SCNX) currently holds an earnings forecast score of 8.00, placing it 55th out of 157 in the Pharmaceuticals industry. Based on analysis from one analyst, the stock has a \"Buy\" rating with an upside potential of 292.67%. The company's expected revenue for t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scnx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:10:09", "published_display": "18 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture\u2019s naloxone nasal spray added to national health plan By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQZjBJZFZGRWROelFUQXc0SVptY2piSlRXYnVVMFU5WnhqTUdMTnBqR2tDYXIwM1FXT2FtNEdMQ295eGVpYjBsSHktUTdiek9fQVg4Z2l5ZmE0TWRlaFpJYVNqYkIwSjE2cW5VSC1WY2R2RW9rMFhnSG96TXhXdVh0amRvTWlCaU9icXdCZk4zdWx1U1ZSQTFuVXptdUJITXF4YWNPYTZUbnd1N1FMZ3FlMHd5ZkhiSUpwdzBDRkM3VQ?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-09T12:17:22+00:00", "published_display": "09 Jun 2026 12:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCIENTURE Secures Formulary Coverage for REZENOPY\u2122 with a Large National Health Plan and Expands Commercial Team", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scienture-secures-formulary-coverage-rezenopy-120500775.html", "source_name": "GlobeNewswire", "published_at": "2026-06-09T12:05:00+00:00", "published_display": "09 Jun 2026 12:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/exclusive-scienture-expands-coverage-opioid-114607922.html", "source_name": "Benzinga", "published_at": "2026-06-09T11:46:07+00:00", "published_display": "09 Jun 2026 11:46", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scienture-present-small-cap-showcase-120000652.html", "source_name": "ACCESS Newswire", "published_at": "2026-06-04T12:00:00+00:00", "published_display": "04 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Secures US Patent Protection for Rezenopy Through 2041", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scienture-secures-us-patent-protection-131534419.html", "source_name": "MT Newswires", "published_at": "2026-06-02T13:15:34+00:00", "published_display": "02 Jun 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCIENTURE Receives U.S. Patent Covering REZENOPY\u2122 (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scienture-receives-u-patent-covering-120500879.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T12:05:00+00:00", "published_display": "02 Jun 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scienture-reports-first-quarter-2026-123800756.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:38:00+00:00", "published_display": "18 May 2026 12:38", "sentiment": "positive", "sentiment_pct": 79, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/scienture-holdings-q1-earnings-snapshot-205811400.html", "source_name": "Associated Press", "published_at": "2026-05-15T20:58:11+00:00", "published_display": "15 May 2026 20:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture secures $11.0 million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of research and development pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPclNkUTRPaWd2clFfMzVqNlJNVzNOWjRMQm45VVhoNlRLaGpCbmVsN21xUk9jeThKYXlqRERsckJQMzRnclFzUF9vOUQ0a2NGWkdsUDJJc3IxWjN5cDFYOTdhWlRaWDRLeU1odTE1cDlqN3FxNmtXaUE3YnNINnQ2RTUtcjVXdEJKRERkUFZQcDhIX3d1QkZFQjB4dE9TTktMbUg3OEhnZ0czOEVSQ3NaMW4wNERPZjFZcWVjVGNPTmdkSFc2bGhSSFNaeVVXdmJheVhZcVNFNUtqM3NLVGdIMW45Q1F5SWs?oc=5", "source_name": "marketscreener.com", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings, Inc. Receives Additional 180-Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Requirement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNaWx1amd5bzI1UGhrYmF0eGdGd1doYmZJZTg2bzhrTmdfdHpTb2NlVzBVSXdjdDNBZGl1VExlMm01d1dYcmdURi1fMUR6d29Hc0hZRzZRcXo5OTNGRFBFNHBjSGJ3WDJ6aHFzNVJzVXFEYUppSmFFODdXZHBYcmNpa09YM1VrSXNlcmhJdU9UZlBBUlJocGxSVTMyOVBSdFR2eG9tbkM4V2xVUW9KUU5BUjJ6ckJnWVVuczRKWXpjRV9JNzdvQXJ6YUM0S2lqVDh1d3BmZ3FveEtHRWJXakh6aXBKUHY4clhmei1lRWZ5Z2tYNEh6OEFEYQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings 10-K: $0.43M Revenue, $(2.70) EPS \u2014 ARBLI\u2122 Launch Drives Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQV2hsYnF4TkFvWjZzR0dxeG9KOXB6VHV3eVU1R1lKcnA2T3E1Qk9oM1NTdFRsVDEzUGlfbFJmMExMSHJGUnd1NG4xU2ZzZ3RkTkdYaU5jWXdsRXpNOVhoU3JMV1dIeEtTWTc1c0JVd3pDWW9fcDN0ZGs5UE50X2lKd3huOGRMSlBBVEVIaFM0M3QyV0Z2UzVtb3RMb0twNmpkU1ItcHFJZkZ6YTRWamVOTl9kdTlsbHA3Wl9lQlNoN0ZYM25fc1JzOWZSZi1TVGlt?oc=5", "source_name": "TradingView", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture (NASDAQ: SCNX) begins Arbli sales; $256M losartan market, 2,500 institutions", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNVkNPdzM4QjBnUzBXZFdzQlh1aXk4UjRfanFDZ21PX2lUTktSUGxKUXg3U2Izamt0eUFaRXdZekRidUk4VmpxYzVVcV91dS14Q3JDbU0tNXc1VDZSVWp6NFBKTFhNVGVIR2lLVGx3MEppVWVmV0NrUDVIcDBqbWZoeEctdzlNc1ZVbS1sR21wYzBiSGRKcUU1UVc1UHJVUVlCeGNSV1JCUU9jS2JpbWQwMXhUajhUT2R0bHhV?oc=5", "source_name": "Stock Titan", "published_at": "2025-10-23T07:00:00+00:00", "published_display": "23 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture (SCNX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9fd2pSRHVSR0p4WUhubkpSZ0RkRGNfQ1FYZk56dm5SOE9sVVlVT3BkYXRCeEdUTVZtbjFyc1hYOHZSQXNObTN2YUZMTEIxR2FqMTFTaUhRdjN1UQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-09-27T14:01:59+00:00", "published_display": "27 Sep 2024 14:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Scienture Holdings Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAJBVV95cUxPY0RKYTNtc1dvQVpBVWVzZHlOUDJfTmF3Wi1GQTQ1dExFUjFzU3U2bXlvM0JleUhxaEdEVXBrX3JmYjYxVmlacGRmcVFobFJodEhmT1hLWjVpY0ZtOVg3YWtLMFBOUk4xeTFWOVpIY1B4TC1XeG5OTS1YMWhFRThUaFlMelRPMmtNNGdhWV9JaHdWdkFxcUZ6OFh2dkszbHlQcTVlcndDeXNDUVVXOEROd1ZEdk5Id0xWX3p5LUNDSFVxUURSYzdvNkRIeFFuZUxhbS1WSmNwOGlZV2Q4Rk1ZTnViSE9mZDkyUktLTW00bVRxTGttZ0UyS2gyMDVnZVV3WWp6MGU5YjRDNkM4UVlreXA0MG5EaE1kYmVGRGJJbWhHOEEtUmNZSlluSTlKVFlWYTRmR0V5c29nbDhHRlZKQlBpSm9FUUhD?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T16:14:45+00:00", "published_display": "13 Jul 2026 16:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings (SCNX) Registration filing Summary", "summary": "Scienture Holdings (SCNX) filed a registration summary outlining its strategic shift from a digital pharmacy marketplace to a specialty pharmaceutical company, focusing on CNS and cardiovascular diseases. The company reported a net loss of $4.4 million for the six months ending J", "url": "https://quartr.com/events/scienture-holdings-inc-scnx-registration-filing_F1ZpJ9do", "source_name": "Quartr", "published_at": "2026-07-11T23:12:50", "published_display": "11 Jul 2026 23:12", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on Top Healthcare Stocks: Scienture Holdings (SCNX), Royalty Pharma (RPRX)", "summary": "Two analysts have issued bullish sentiments on healthcare stocks Scienture Holdings (SCNX) and Royalty Pharma (RPRX). Maxim Group analyst Naz Rahman reiterated a Buy rating on Scienture Holdings with a $1.50 price target, while Bank of America Securities analyst Jason Gerberry ma", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3239239/analysts-are-bullish-on-top-healthcare-stocks-scienture-holdings-scnx-royalty-pharma-rprx/", "source_name": "The Globe and Mail", "published_at": "2026-07-11T22:47:05", "published_display": "11 Jul 2026 22:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maxim Group Maintains Scienture Holdings(SCNX.US) With Buy Rating, Maintains Target Price $1.5", "summary": "Maxim Group has reiterated its Buy rating for Scienture Holdings (SCNX.US), maintaining a target price of $1.5. This indicates continued confidence from the analyst firm in the company's stock performance.", "url": "https://www.moomoo.com/news/post/72791205/maxim-group-maintains-scienture-holdings-scnxus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-11T15:40:29", "published_display": "11 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why", "summary": "Scienture Holdings (NASDAQ: SCNX) shares surged over 20% pre-market due to the impending commercial launch of its high-dose naloxone nasal spray, REZENOPY, with shipments to wholesalers expected this month and retail availability in August. This follows a previous successful prod", "url": "https://www.sahmcapital.com/news/content/scienture-holdings-stock-jumps-over-20-pre-market-heres-why-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T13:40:29", "published_display": "11 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings, Inc. Completes Manufacturing of Commercial Launch Inventory and Begins Shipments of Rezenopy Nasal Spray 10 Mg to U.S. Pharmaceutical Wholesalers", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNcWlTQmJYcF9DeDJsRTdOdGtFaGNmNU9ITFFaSDZjMlIySE1QMEpFcEFIMWF4Tl8tcFdMYnN0V3R4b1lfdGNucUVSa2ZpMnl3STVwSXZZbG9GUlpJYk9qMDFmVk9hZW9rX2dFQVRvNkhxQjFSRS1LM0FjdlBEeDZHckpLcnhVM0hZb2ZKRFd3cWUxbEtNZXU4LVRWYjl0OGhfSnZVM2NQUWg5UHBuajBnMUZrVXRSZWxQUzhLY19SbmswNVdYaEdMeDN2RUNJMTBNYjQ5UjhWUFl1eU5wSUhSYnZBck1xUQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-09T16:35:57+00:00", "published_display": "09 Jul 2026 16:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture (SCNX) Prepares for Rezonopy Nasal Spray Launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQcF8yZFlMUEtJczdRRzhoREEyOFBFN05CZzZ0Z1BJaHFfd1B0TkZGZUZPUjB6Z2dQR0pqdFNIRzZ1bkhHSmxNaWRsNUctOUkyekE2amkzZVc0VXNWVUhmdGZrN3FpSEt0UEx4WkVoZ2dJeXdVUkVTNkx2WlByVE4ycFFNd3NENzdTTG5rNVE0TjN0OGxLbTNDS0d3?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-09T14:18:04+00:00", "published_display": "09 Jul 2026 14:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture completes manufacturing for naloxone spray launch", "summary": "Scienture Holdings Inc. has completed manufacturing of REZENOPY naloxone hydrochloride nasal spray 10 mg and will begin shipments to U.S. pharmaceutical wholesalers this month, with commercial availability expected in August. The FDA-approved product targets a U.S. naloxone marke", "url": "https://www.investing.com/news/company-news/scienture-completes-manufacturing-for-naloxone-spray-launch-93CH-4784007", "source_name": "Investing.com", "published_at": "2026-07-09T12:40:53", "published_display": "09 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY\u2122 (naloxone hydrochloride) to Wholesalers", "summary": "SCIENTURE Holdings, Inc. has finished manufacturing commercial inventory for REZENOPY\u2122 (naloxone hydrochloride) Nasal Spray 10 mg and will begin shipments to U.S. pharmaceutical wholesalers later in July. This marks a significant commercial milestone for the company, with REZENOP", "url": "https://www.marketscreener.com/news/scienture-announces-commercial-inventory-readiness-and-july-shipments-of-rezenopya-naloxone-hydro-ce7f5eded98ff323", "source_name": "www.marketscreener.com", "published_at": "2026-07-09T11:40:53", "published_display": "09 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY (Naloxone Hydrochloride) to Wholesalers", "summary": "SCIENTURE Holdings, Inc. announced that it has completed manufacturing of its commercial launch inventory for REZENOPY (naloxone hydrochloride) Nasal Spray 10 mg and will begin shipments to U.S. pharmaceutical wholesalers later in July 2026. Commercial availability for purchase i", "url": "https://www.moomoo.com/news/post/72715872/scienture-announces-commercial-inventory-readiness-and-july-shipments-of-rezenopy", "source_name": "Moomoo", "published_at": "2026-07-09T11:40:53", "published_display": "09 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture readies highest-dose naloxone spray for August sale", "summary": "Scienture (NASDAQ: SCNX) has completed the commercial launch inventory for REZENOPY\u2122 (naloxone hydrochloride) Nasal Spray 10 mg and will begin shipments to U.S. wholesalers in July 2026, with commercial availability expected in August. REZENOPY is the highest-dose FDA-approved na", "url": "https://www.stocktitan.net/news/SCNX/scienture-announces-commercial-inventory-readiness-and-july-gjrls795bwet.html", "source_name": "Stock Titan", "published_at": "2026-07-09T11:40:52", "published_display": "09 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Scienture Holdings, Inc. \u2013 NASDAQ:SCNX", "summary": "The article displays the \"Price to sales forward\" metric for Scienture Holdings, Inc. (NASDAQ: SCNX) on the TradingView platform. It provides a financial metric for the company, accessible through various market data and analysis tools. The page itself is a snapshot of financial ", "url": "https://www.tradingview.com/symbols/NASDAQ-SCNX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T17:42:17", "published_display": "30 Jun 2026 17:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Scienture Holdings, Inc. \u2013 NASDAQ:SCNX", "summary": "This article mentions the \"Price to book forward\" for Scienture Holdings, Inc. (NASDAQ: SCNX). It appears to be a stub or a title for a financial data point without further textual analysis or details provided. The content primarily consists of navigation and copyright informatio", "url": "https://www.tradingview.com/symbols/NASDAQ-SCNX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:27:45", "published_display": "30 Jun 2026 04:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings, Inc. Actuals & Estimates (NASDAQ:SCNX)", "summary": "This article provides an overview of Scienture Holdings, Inc. (SCNX) financial actuals and estimates, including its current stock price, volatility, market cap, and future earnings reports. It details past stock performance, analyst forecasts, and answers frequently asked questio", "url": "https://www.tradingview.com/symbols/NASDAQ-SCNX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:11:13", "published_display": "25 Jun 2026 18:11", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCNX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Scienture Holdings, Inc. (SCNX) stock. An analyst has set a 1-year price target of $1.50, though the stock has seen significant declines over the past year. The article also includes financial data, earnings information, and a", "url": "https://www.tradingview.com/symbols/NASDAQ-SCNX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:10:30", "published_display": "25 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings Inc (SCNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Scienture Holdings Inc (SCNX), highlighting its current price momentum, support and resistance levels, and indicator and moving average signals. It notes that SCNX's stock price is trading between resistance at $0.43 and support at $0", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scnx/technical", "source_name": "TradingKey", "published_at": "2026-06-24T15:09:41", "published_display": "24 Jun 2026 15:09", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCIENTURE Expands Arbli\u2122 Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide", "summary": "SCIENTURE Holdings, Inc. announced a significant expansion in the commercialization of its product, Arbli\u2122 (losartan potassium oral suspension), by securing additional payor coverage for approximately 12.5 million more lives.", "url": "https://finance.yahoo.com/healthcare/articles/scienture-expands-arbli-payor-coverage-120500712.html", "source_name": "Market source", "published_at": "2026-06-22T17:11:25", "published_display": "22 Jun 2026 17:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings (Nasdaq:SCNX) - Stock Analysis", "summary": "This article provides a stock analysis of Scienture Holdings (Nasdaq: SCNX), highlighting its undervaluation, forecast earnings growth, and risks such as shareholder dilution and volatile share price. It details recent commercialization efforts for its drug Arbli and FDA-approved", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-scnx/scienture-holdings", "source_name": "Simply Wall Street", "published_at": "2026-06-21T02:09:10", "published_display": "21 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings Inc (SCNX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Scienture Holdings Inc (SCNX), highlighting its current valuation score of 8.95 within the Pharmaceuticals industry. It details the company's P/E ratio, noting it is significantly below its recent high. The article also mentions that ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scnx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T01:39:25", "published_display": "19 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture stock rises after adding 12.5M covered lives for Arbli", "summary": "Scienture Holdings Inc (NASDAQ: SCNX) shares rose 5.8% after announcing additional payor coverage for its drug Arbli, a losartan potassium oral suspension. This expanded coverage adds approximately 12.5 million covered lives through Medicare Part D and other healthcare channels, ", "url": "https://ng.investing.com/news/stock-market-news/scienture-stock-rises-after-adding-125m-covered-lives-for-arbli-93CH-2565621", "source_name": "Investing.com Nigeria", "published_at": "2026-06-19T00:39:50", "published_display": "19 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings Inc (SCNX) Institutional Confidence", "summary": "This article from TradingKey provides an overview of the institutional confidence in Scienture Holdings Inc (SCNX), specifically detailing changes in institutional shareholdings. Several individuals and firms, including Narasimhan (Mani), Hariharan (Shankar Ph.D.), and Geode Capi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scnx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T13:10:24", "published_display": "18 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings Inc (SCNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article provides a revenue breakdown for Scienture Holdings Inc (SCNX), noting that relevant data for business segments and regional revenue contribution has not yet been disclosed by the company for FY2025 and earlier quarters. It highlights that the company's stock closed a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scnx/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T12:39:02", "published_display": "18 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX)", "summary": "Analysts are split on their ratings for healthcare companies Moderna (MRNA) and Scienture Holdings (SCNX). William Blair analyst Myles Minter reiterated a Hold rating for Moderna, while Maxim Group analyst Naz Rahman reiterated a Buy rating for Scienture Holdings with a $1.50 pri", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MRNA-Q/pressreleases/2519934/analysts-conflicted-on-these-healthcare-names-moderna-mrna-and-scienture-holdings-scnx/", "source_name": "The Globe and Mail", "published_at": "2026-06-18T12:39:01", "published_display": "18 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture expands payor coverage for Arbli by 12.5M lives", "summary": "Scienture Holdings Inc. has announced a significant expansion in payor coverage for its oral suspension, Arbli, adding approximately 12.5 million covered lives through Medicare Part D supplement plans and other commercial and government healthcare channels. This move aims to incr", "url": "https://www.investing.com/news/company-news/scienture-expands-payor-coverage-for-arbli-by-125m-lives-93CH-4749779", "source_name": "Investing.com", "published_at": "2026-06-18T12:10:49", "published_display": "18 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture (SCNX) Advances Commercialization of Arbli", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNbUNCNUVWbS1WRFNKZEpla0hfWWFPeFF0amQ0bmdrYV9pck9NQnpadlhDeGEzM3RXenBHNnZ1ZUZ0RTloMUpYdHhZZnYxZXFCX1lVNEd2R2tWenlTS0p2bWJkYTlOQW5pNnRxcHFCR1hUYUwxVWszX3hXb3FXNnNGZFAyU0ZyQTRyWUJ3TlFUX1dFbmp2QTFKcmw2RWx6elhDVHY4?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings Inc (SCNX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Scienture Holdings Inc (SCNX) currently holds a financial score of 6.07, ranking 148th out of 157 in the Pharmaceuticals industry, indicating robust financial status but low operating efficiency. The company recently reported a quarterly revenue of 56.33K, marking a significant y", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scnx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T06:10:09", "published_display": "18 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCIENTURE Expands Arbli Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide", "summary": "SCIENTURE has significantly expanded payor coverage and commercial access for its medication, Arbli, adding approximately 12.5 million covered lives across the nation. This expansion includes new agreements with major payors like Capital Blue Cross in Pennsylvania and Excellus Bl", "url": "https://www.moomoo.com/news/post/71732053/scienture-expands-arbli-payor-coverage-and-commercial-access-adding-approximately", "source_name": "Moomoo", "published_at": "2026-06-18T06:09:20", "published_display": "18 Jun 2026 06:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings Inc (SCNX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Scienture Holdings Inc (SCNX) currently holds an earnings forecast score of 8.00, placing it 55th out of 157 in the Pharmaceuticals industry. Based on analysis from one analyst, the stock has a \"Buy\" rating with an upside potential of 292.67%. The company's expected revenue for t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scnx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:10:09", "published_display": "18 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture\u2019s naloxone nasal spray added to national health plan By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQZjBJZFZGRWROelFUQXc0SVptY2piSlRXYnVVMFU5WnhqTUdMTnBqR2tDYXIwM1FXT2FtNEdMQ295eGVpYjBsSHktUTdiek9fQVg4Z2l5ZmE0TWRlaFpJYVNqYkIwSjE2cW5VSC1WY2R2RW9rMFhnSG96TXhXdVh0amRvTWlCaU9icXdCZk4zdWx1U1ZSQTFuVXptdUJITXF4YWNPYTZUbnd1N1FMZ3FlMHd5ZkhiSUpwdzBDRkM3VQ?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-09T12:17:22+00:00", "published_display": "09 Jun 2026 12:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCIENTURE Secures Formulary Coverage for REZENOPY\u2122 with a Large National Health Plan and Expands Commercial Team", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scienture-secures-formulary-coverage-rezenopy-120500775.html", "source_name": "GlobeNewswire", "published_at": "2026-06-09T12:05:00+00:00", "published_display": "09 Jun 2026 12:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/exclusive-scienture-expands-coverage-opioid-114607922.html", "source_name": "Benzinga", "published_at": "2026-06-09T11:46:07+00:00", "published_display": "09 Jun 2026 11:46", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scienture-present-small-cap-showcase-120000652.html", "source_name": "ACCESS Newswire", "published_at": "2026-06-04T12:00:00+00:00", "published_display": "04 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Secures US Patent Protection for Rezenopy Through 2041", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scienture-secures-us-patent-protection-131534419.html", "source_name": "MT Newswires", "published_at": "2026-06-02T13:15:34+00:00", "published_display": "02 Jun 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCIENTURE Receives U.S. Patent Covering REZENOPY\u2122 (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scienture-receives-u-patent-covering-120500879.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T12:05:00+00:00", "published_display": "02 Jun 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scienture-reports-first-quarter-2026-123800756.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:38:00+00:00", "published_display": "18 May 2026 12:38", "sentiment": "positive", "sentiment_pct": 79, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/scienture-holdings-q1-earnings-snapshot-205811400.html", "source_name": "Associated Press", "published_at": "2026-05-15T20:58:11+00:00", "published_display": "15 May 2026 20:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture secures $11.0 million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of research and development pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPclNkUTRPaWd2clFfMzVqNlJNVzNOWjRMQm45VVhoNlRLaGpCbmVsN21xUk9jeThKYXlqRERsckJQMzRnclFzUF9vOUQ0a2NGWkdsUDJJc3IxWjN5cDFYOTdhWlRaWDRLeU1odTE1cDlqN3FxNmtXaUE3YnNINnQ2RTUtcjVXdEJKRERkUFZQcDhIX3d1QkZFQjB4dE9TTktMbUg3OEhnZ0czOEVSQ3NaMW4wNERPZjFZcWVjVGNPTmdkSFc2bGhSSFNaeVVXdmJheVhZcVNFNUtqM3NLVGdIMW45Q1F5SWs?oc=5", "source_name": "marketscreener.com", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings, Inc. Receives Additional 180-Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Requirement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNaWx1amd5bzI1UGhrYmF0eGdGd1doYmZJZTg2bzhrTmdfdHpTb2NlVzBVSXdjdDNBZGl1VExlMm01d1dYcmdURi1fMUR6d29Hc0hZRzZRcXo5OTNGRFBFNHBjSGJ3WDJ6aHFzNVJzVXFEYUppSmFFODdXZHBYcmNpa09YM1VrSXNlcmhJdU9UZlBBUlJocGxSVTMyOVBSdFR2eG9tbkM4V2xVUW9KUU5BUjJ6ckJnWVVuczRKWXpjRV9JNzdvQXJ6YUM0S2lqVDh1d3BmZ3FveEtHRWJXakh6aXBKUHY4clhmei1lRWZ5Z2tYNEh6OEFEYQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture Holdings 10-K: $0.43M Revenue, $(2.70) EPS \u2014 ARBLI\u2122 Launch Drives Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQV2hsYnF4TkFvWjZzR0dxeG9KOXB6VHV3eVU1R1lKcnA2T3E1Qk9oM1NTdFRsVDEzUGlfbFJmMExMSHJGUnd1NG4xU2ZzZ3RkTkdYaU5jWXdsRXpNOVhoU3JMV1dIeEtTWTc1c0JVd3pDWW9fcDN0ZGs5UE50X2lKd3huOGRMSlBBVEVIaFM0M3QyV0Z2UzVtb3RMb0twNmpkU1ItcHFJZkZ6YTRWamVOTl9kdTlsbHA3Wl9lQlNoN0ZYM25fc1JzOWZSZi1TVGlt?oc=5", "source_name": "TradingView", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture (NASDAQ: SCNX) begins Arbli sales; $256M losartan market, 2,500 institutions", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNVkNPdzM4QjBnUzBXZFdzQlh1aXk4UjRfanFDZ21PX2lUTktSUGxKUXg3U2Izamt0eUFaRXdZekRidUk4VmpxYzVVcV91dS14Q3JDbU0tNXc1VDZSVWp6NFBKTFhNVGVIR2lLVGx3MEppVWVmV0NrUDVIcDBqbWZoeEctdzlNc1ZVbS1sR21wYzBiSGRKcUU1UVc1UHJVUVlCeGNSV1JCUU9jS2JpbWQwMXhUajhUT2R0bHhV?oc=5", "source_name": "Stock Titan", "published_at": "2025-10-23T07:00:00+00:00", "published_display": "23 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scienture (SCNX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9fd2pSRHVSR0p4WUhubkpSZ0RkRGNfQ1FYZk56dm5SOE9sVVlVT3BkYXRCeEdUTVZtbjFyc1hYOHZSQXNObTN2YUZMTEIxR2FqMTFTaUhRdjN1UQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-09-27T14:01:59+00:00", "published_display": "27 Sep 2024 14:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 80, "total_relevant": 41, "sentiment_summary": {"positive": 17, "negative": 4, "neutral": 20, "score": 56, "total": 41, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 15.4, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 4.75, "count": 8}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 0.37, "latest_week": "2026-07-10", "one_week_move": 7.6, "four_week_move": -2.1, "twelve_week_move": -6.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.231227, "market_dynamics_buy_signal": false, "relative_strength": -55.421938, "fair_value_gap": -89.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 39.65, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.6% over one week, -2.1% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingKey", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "GlobeNewswire", "count": 3}, {"label": "The Globe and Mail", "count": 2}, {"label": "marketscreener.com", "count": 2}, {"label": "GuruFocus", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 41}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 8}, {"label": "Analyst action", "count": 4}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "41", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+7.6% over one week, -2.1% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Scienture Holdings Company Profile & Introduction"}], "updated_at": "2026-07-16T18:22:46.121647+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}